E.M. Dmytriieva

E.M. Dmytriieva

Auto-generated profile, based on publicly available information

E.M. Dmytriieva

National Pirogov Memorial Medical University, Vinnytsia, Ukraine

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2025 in Infusion & Chemotherapy
Verified
Journal Article
Open access
SZS.V. Zaikov
S.V. Zaikov
MLM.A. Lykova
M.A. Lykova
TKT.V. Kyrylenko
T.V. Kyrylenko
EDE.M. Dmytriieva
E.M. Dmytriieva
AGA.V. Gaponiuk
A.V. Gaponiuk
BACKGROUND. Vasomotor rhinitis represents a significant global health burden, with prevalence rates ranging from 5 to 25 %. It is a subtype of non-allergic rhinitis, a heterogeneous group of disorders characterized by rhinitis symptoms not caused by atopy or infection, which are sometimes grouped with other phenotypes such as gustatory, hormonal, or drug-induced rhinitis. In contrast to allergic rhinitis, which involves IgE-mediated immune responses, vasomotor rhinitis is driven by neurogenic and autonomic dysfunction. Previously, several authors proposed using the terms “vasomotor rhinitis” and “non-allergic rhinopathy” concurrently, or even classifying allergic rhinitis under vasomotor rhinitis. This creates discrepancies in interpreting the concepts of “vasomotor rhinitis”, “non-allergic rhinopathy”, and “allergic rhinitis”, hindering a clear understanding of management approaches for the respective patient categories. OBJECTIVE. To analyze available data on the etiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of vasomotor rhinitis. MATERIALS AND METHODS. A search for available information sources, analytical processing, and discussion of the obtained results. RESULTS AND DISCUSSION. Vasomotor rhinitis is a common, yet poorly studied, type of chronic rhinitis that is currently believed to be neurogenic in origin. Several authors use the term “non-allergic rhinopathy” instead of “vasomotor rhinitis”, which complicates the understanding of this issue. Currently, there are no unified international diagnostic criteria for vasomotor rhinitis. In real clinical practice, physicians should perform differential diagnosis between vasomotor and allergic rhinitis (using specific allergodiagnostic methods), as well as exclude infectious rhinitis, drug-induced rhinitis, and chronic rhinosinusitis (using history taking, endoscopy, and other supplementary investigation methods). The majority of patients with vasomotor rhinitis respond adequately to treatment with topical saline solutions, topical antihistamines, corticosteroids, and ipratropium sprays, all of which alleviate rhinitis symptoms. Individuals who are refractory to traditional treatment may undergo therapy with capsaicin, botulinum toxin, and posterior nasal nerve ablation using radiofrequency ablation or cryotherapy. Currently, biological agents and neuromodulatory treatments are at various stages of investigation, focusing on the effect of such targeted therapy on type 2 inflammation, specifically the blockade of interleukin-4 and -13. Despite the encouraging nature of this data for other rhinitis subtypes, their role in vasomotor rhinitis remains unclear. Standardized and highly agreed-upon diagnostic criteria for vasomotor rhinitis must be developed to allow for more precise patient classification through phenotyping, enable targeted therapeutic selection, and establish a reliable evidence base regarding the efficacy and safety of treatment methods for this patient category. CONCLUSIONS. Patients with vasomotor rhinitis often seek medical attention from allergists, otolaryngologists, and physicians of other specialties. Currently, there is no standardized approach to the management of such patients among various specialists. The issue of vasomotor rhinitis remains relevant and poorly understood, but the approaches to managing these patients must be unified.

10 May 2026 in EMERGENCY MEDICINE
Verified
Journal Article
Open access
PDF file
ODO.I. Datsiuk
O.I. Datsiuk
MSM.V. Svirhun
M.V. Svirhun
OHO.S. Honcharuk
O.S. Honcharuk
LDL.V. Datsiuk
L.V. Datsiuk
OKO.V. Kutsyk
O.V. Kutsyk
VOV.A. Ozymyi
V.A. Ozymyi
Background. Postoperative cognitive impairment is a predictor of persistent cognitive dysfunction and increases the risk of dementia. Over the past two decades, there has been an increase in the number of orthopedic procedures performed under spinal anesthesia for acute trauma or degenerative joint disease. The occurrence of cognitive deficits in the early postoperative period in the elderly is a proven fact. The problem of analyzing diagnostic criteria and adequate neuroprotective correction of postoperative cognitive dysfunction in hip arthroplasty remains not fully resolved. Purpose: to study the negative dynamics of cognitive functions at different times after hip arthroplasty under spinal anesthesia. Materials and methods. The number of patients included in the study was 120. All participants were treated at the trauma unit of the Vinnytsia City Clinical Emergency Hospital. The Mini-Mental State Examination (MMSE) was used as one of the main assessment scales in postoperative cognitive dysfunction. Neurocognitive testing to determine the state of higher nervous activity was performed the day before operation, repeated assessment was carried out on the 4th and 7th days after surgery, and the day before discharge from the hospital. Statistical data processing was performed using the capabilities of spreadsheets of Microsoft Excel and the statistical information processing package SPSS 23.0. Results. In the vast majority (77.1 %) of patients on the 4th day after hip arthroplasty, the negative dynamics of cognitive function was manifested in the form of the appearance of mild cognitive impairment with their absence at the time of hospitalization and the appearance of cognitive disorders of moderate dementia level in the presence of their mild degree at the time of hospitalization. On the 7th day versus the 4th day, a decrease in cases of change in cognitive status is recorded compared to the indicators at the time of hospitalization. And the day before discharge, only 13 out of 35 (37.1 %) cases had negative dynamics of cognitive function; from the total sample, the share of these patients was almost 11 %. Conclusions. Based on the analysis of data on the state of changes in cognitive function, when comparing the postoperative period with the preoperative state, the MMSE in the perioperative period can be used to diagnose cognitive disorders and as a criterion for the effectiveness of correction of cognitive impairment in these patients for the purpose of further therapy.

19 September 2024 in Asthma and allergy
Verified
Journal Article
Open access
ВБВ. Д. Бабаджан
В. Д. Бабаджан
СЗС. В. Зайков
С. В. Зайков
МЛМ. А. Ликова
М. А. Ликова
ЕДЕ. М. Дмитрієва
Е. М. Дмитрієва
Резюме. Мета огляду полягає у деталізації тригерів анафілаксії, зокрема лікарських засобів, таких як антибіотики, хіміопрепарати, моноклональні антитіла, анестетики та нейром’язові блокатори, β-блокатори та інгібітори АПФ, впливі кофакторів, мастоцитозу і клональних порушень тучних клітин на частоту розвитку анафілаксії. Важливе значення має надання алергологам та медичним працівникам знань про нові підходи щодо ведення пацієнтів з анафілаксією, що дозволить покращити її діагностику, лікування та профілактику. Встановлена наявність кофакторів анафілаксії, які не є частиною імунологічного механізму, але модулюють початок анафілаксії, оскільки в їх присутності анафілактичні реакції стають більш серйозними та/або виникають при нижчій концентрації алергену. Діагностика анафілаксії ґрунтується на проведенні шкірних тестів, вимірюванні специфічних IgE до харчових продуктів, ліків та отрути комах. Ефективність невідкладної допомоги при виникненні анафілаксії залежить від раннього її розпізнавання та швидкого застосування епінефрину (адреналіну).

24 September 2026 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
SZS.V. Zaikov
S.V. Zaikov
IKI.K. Kalikina
I.K. Kalikina
TKT.V. Kyrylenko
T.V. Kyrylenko
EDE.M. Dmytriieva
E.M. Dmytriieva
BACKGROUND. Intravenous iodine-based contrast media (ICM) are widely used in medical practice worldwide. For instance, in the United States alone, 80 million computed tomography scans were performed in 2019, with ICM used in approximately 37.5 % of them. Adverse reactions to these agents may occur immediately following administration or be delayed. Currently, physicians across various specialties lack sufficient knowledge regarding the clinical presentation, diagnosis, treatment, and prevention of hypersensitivity reactions (HSRs) to ICM.MATERIALS AND METHODS. A search for available sources of information, their analytical processing, and a discussion of the obtained results.RESULTS AND DISCUSSION. Mild immediate-type HSRs occur more frequently than delayed ones and manifest as localized urticaria and pruritus, isolated papular eruptions, a sensation of itching or scratching in the throat, nasal congestion, sneezing, rhinorrhea, and conjunctivitis. Moderate HSRs present with signs and symptoms that are more pronounced than those of mild reactions but do not alter vital signs. These may include generalized urticaria, facial swelling, throat tightness, hoarseness, wheezing, and bronchospasm. Such reactions typically require pharmacological treatment and have the potential to progress to severe reactions if the symptoms are not addressed. Severe reactions are characterized by signs and symptoms that are often life-threatening and may lead to permanent disability or death if appropriate measures are not taken. Delayed reactions to ICM are most frequently accompanied by mild cutaneous manifestations associated with T-cell mechanisms. However, clinical cases of severe cutaneous adverse reactions – such as acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), and Stevens-Johnson syndrome / toxic epidermal necrolysis – have also been described. Diagnosing HSRs to ICM involves obtaining an allergy history and performing skin tests with these agents, with the choice of test depending on the mechanism of the immune-mediated reaction. The management strategy for patients with hypersensitivity to ICM has not yet been fully standardized; currently, it relies on substituting the causative agent with an alternative one and, where indicated, performing rapid desensitization.CONCLUSIONS. Despite the research findings regarding adverse reactions to ICM, a number of unresolved issues remain that require further study. These include: 1) the necessity of documenting all adverse reactions associated with ICM use in medical records, specifically identifying the causative agent responsible for the reaction; description of the reaction type using terminology employed in the allergology and immunology literature, as well as a description of the treatment received by the patient; 2) organization of the identification of individuals at increased risk of HSRs to ICM and determination of the benefits of risk-reduction measures – specifically premedication with antihistamines and corticosteroids; 3) further determination of the value of a strategy for switching contrast agents; 4) establishment of a national registry of patients with HSRs, particularly to ICM; 5) incorporation of serum tryptase level measurements – following a severe reaction to ICM – into risk stratification for future contrast-enhanced examinations; 6) study of the diagnostic value and potential role of skin testing in selecting safe alternative ICM; 7) further research into the efficacy and safety of rapid ICM desensitization.